Literature DB >> 21694928

Tuberculosis in children undergoing hemodialysis.

Gargah Tahar1, Rim Goucha-Louzir, Lakhoua Mohamed Rachid.   

Abstract

UNLABELLED: Tuberculosis (TB) remains a public health problem in Tunisia. Its incidence is higher in immunocompromised hosts than in the general population. In children and during hemodialysis, TB is characterized by the frequency of extrapulmonary localizations and diagnostic difficulties. The aim of this retrospective study is to evaluate the incidence of TB in Tunisian children undergoing hemodialysis and to determine its clinical features as well as the results of chemotherapy.
METHOD: This retrospective study includes seven TB children among 112 children on hemodialysis at the pediatric nephrology department in Charles Nicolle Hospital from 2002 to 2008. The diagnosis of TB was established by a combination of clinical, radiological, biochemical, microbiological, and histological examinations. Treatment with anti-TB drugs, the results of therapy, and the outcome of patients were noted.
RESULTS: There were four girls and three boys aged 10 to 16 years (mean, 13 years). They had been on hemodialysis for 2 to 5 years (mean, 3 years). Noted clinical features were weight loss and fever in five cases, chest pain in one case, cervical lymph node in one case, and spinal pain in one case. The organ systems involved were pleural in two cases, pulmonary in one case, peritoneal in one case, cervical lymphatic in one case, and spinal in one case. One patient was treated empirically with a good response. Diagnosis was made by isolation of mycobacterium TB in three cases, by specific histological signs observed in a lymph node biopsy in one case, in peritoneal biopsy in one case, and in discovertebral biopsy in one case. In the remaining patient, the clinical and radiological presentations were compatible with pulmonary TB. All patients received four anti-TB drugs: isoniazid, rifampicin, pyrazinamide, and ethambutol. One patient died with miliary TB. The other patients had favorable outcomes.
CONCLUSIONS: TB in hemodialysis children has a nonspecific clinical presentation. Extrapulmonary locations are most common. Diagnosis is often difficult, but successful outcomes are possible when made at an early stage. 2010 Tahar et al, publisher and licensee Dove Medical Press Ltd.

Entities:  

Keywords:  child; hemodialysis; tuberculosis

Year:  2010        PMID: 21694928      PMCID: PMC3108780          DOI: 10.2147/ijnrd.s7568

Source DB:  PubMed          Journal:  Int J Nephrol Renovasc Dis        ISSN: 1178-7058


Introduction

The incidence of tuberculosis (TB) decreased in recent years in Tunisia due to effective vaccination. The annual incidence is estimated at 3.5 per 100,000 children.1 Immunocompromised patients, such as those with end-stage renal failure requiring hemodialysis, have an increased risk of developing TB infection. This risk has been estimated as nearly 10- to 25-fold higher among hemodialysis patients than among the general population.2 We report the incidence of TB in normal children as well as in hemodialysis children. We discuss the clinical characteristics, diagnostic procedures, and clinical outcomes for TB children on hemodialysis.

Patients and methods

We retrospectively analyzed all hemodialysis patients aged less than 18 years in whom the diagnosis of TB was presumptive or confirmed from January 2002 to December 2008. One hundred twelve patients were enrolled. Seven patients were diagnosed with TB. Of these, three cases were considered presumptive, three patients were noted to have positive mycobacterium TB culture, and the other was empirically treated for TB with a good response. The following data were collected for each patient: epidemiological characteristics, risk factors, duration of hemodialysis, clinical symptoms, diagnostic methods, treatment, and TB evolution.

Results

Among 112 children treated with hemodialysis during the study period, we noted seven cases (25%) of TB disease: four females and three males with an average age of 13 years (range, 10–16 years). Their duration on hemodialysis ranged from 2 to 5 years (mean, 3 years). The presenting clinical features were weight loss and fever in five cases, chest pain in one case, spinal pain in one case, and cervical lymphadenopathy in one case. Tuberculin skin test was negative in all patients. Chest X-ray showed an abundant pleural effusion in two cases and a miliary TB in one case. In these three patients, sputum samples were smear-negative. The fluid from patients with pleurisy showed exudates rich in lymphocyte (95%). Acid-fast smears using Zeihl–Neelsen acid fast stain and culture in Lowenstein–Jensen medium were performed but proved to be negative. Caseous granulomas were found in pleural biopsy in our patients with TB pleurisy. The culture of tissue biopsy specimens revealed mycobacterium TB in both patients. In patients with peritoneal TB, the diagnosis was established by data from the peritoneal biopsy done by laparoscopy (caseous granulomas). In the case of miliary TB, sputum culture was positive. In another patient, the clinical and radiological presentations were compatible with pulmonary TB. Noted improvement after anti-TB therapy confirmed this diagnosis. The clinical characteristics of our patients are illustrated in Table 1.
Table 1

Clinical details of children with tuberculosis

Patient no.
1234567
Age at diagnosis (years)10121213141416
SexFFMFMFM
Underlying renal diseasePrimary hyperoxaliuriaNephronophtisisUropathyUropathyUnknownSteroid-resistant nephrotic syndromeAlport syndrome
Duration of hemodialysis (years)2,532,52353
SymptomsFeverCough weight lossFeverCough weight lossCervical lymph nodeFeverCough chest painFever weight lossSpinal pain weight lossFeverCough weight loss
Site of tuberculosisPulmonaryPulmonaryCervical lymphadenitisPleuralPeritonealSpondylodiscitisPleural
DiagnosisClinical features: fever, cough and weight loss. Chest X ray finding: Noncavitary infiltrates located in upper right lung. No hilar or mediastinal lymph nodeSputum culture positiveHistology of excised cervical nodes: Granuloma with central caseation necrosis culture (−)Pleural biopsy Caseous granulomas Culture (+)Peritoneal biopsy (laparoscopy) Granuloma with central caseation necrosisCT-guided percutaneaous disc biopsy Caseation necrosis Culture (−)Pleural biopsy Caseous granulomas Culture (+)
OutcomeCuredDiedCuredCuredCuredCuredCured

Abbreviation: CT, computed tomography.

Four drugs, isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), and ethambutol (EMB) were administered orally to six patients initially for three months followed by only INH and RIF for a further six months to complete a nine-month therapy. Drugs were administered on dialysis days following the session of dialysis (three days per week). The outcome was favorable. In one patient with miliary TB, INH and RIF was used intravenously. He died at the beginning of treatment. TB was considered as the direct cause of death for this patient.

Discussion

Uremic adults are more susceptible to TB infection due to pathological changes in the airways and impairment in cellular immunity.3 Dialysis increases these immunological impairments through depletion of useful proteins, trace metals, and vitamins; it also induces an immune response through biocompatibility of dialysis membrane and dialysis fluid or entry of microorganisms.4 Few data are available for uremic children. To our knowledge, nothing has been published in the English literature on TB in hemodialysis children. However, the most recent publication about the child on dialysis reported four cases of TB in children undergoing continuous ambulatory peritoneal dialysis in Turkey.5 According to this study, the incidence of TB in children on dialysis is much lower than in adults on dialysis (23.6% versus 5.7%). This has been attributed to the vaccination program which begins at the age of two months and repeated at the age of seven and 12 years. In Tunisia, the vaccination schedule is similar to Turkey apart from the first dose being given immediately at birth then improving immunization at an early age and before the installation of chronic renal disease. The emergence of TB infection in uremic adults is observed during the early years of hemodialysis. During this phase, the cell-mediated immunity is compromised and promotes infection, especially TB.6 Mesiha and colleagues5 studied children undergoing peritoneal dialysis, and noted that the diagnosis of TB was made during the first year of dialysis in three patients and before dialysis in another patient. In our study, TB infection took place 24 months after beginning hemodialysis. The mode of contamination is probably a reactivation of a pre-existing focus but in our study, the TB may be due to an airborne spread in the hospital community with respect to the interval between the beginning of dialysis and diagnosis of TB. Clinical presentation of TB may be insidious and nonspecific, mimicking uremic symptoms. There are clinical situations that alert us to the presence of TB such as unexplained fever, anorexia, deterioration of nutritional heath, and spinal pain which is often associated to renal osteodystrophy. The diagnosis of TB is difficult to establish in the case of renal failure by simply using traditional tests. The tuberculin skin test is often negative. Bacteriological proof is rarely obtained by traditional tests such as Zeihl–Neelsen staining, culture, or polymerase chain reaction.7 Thus, new, rapid, and it is imperative to utilize accurate diagnostic methods such as blood test measuring the interferon-γ released by stimulated T cells.8 In our study, and because of the unavailability of these modern methods, invasive diagnostic procedures were performed to prove the TB infection: pleural biopsy, peritoneal biopsy, and percutaneaous disc biopsy. Histopathological examination and culture of tissue obtained by biopsy identified the mycobacterium TB in two cases. TB has been described in uremic patients along with an infection with predominantly extra pulmonary involvement.9 During dialysis, pulmonary TB with cavities was minor whereas extrapulmonary TB and miliary TB were major.10 Our data confirm these findings since we found only two patients with pulmonary TB among seven cases. Apart from the diagnostic difficulties, TB in patients undergoing hemodialysis have a real therapeutic problem. The bioavailability of most drugs are altered by renal failure and hemodialysis. The half-life of INH is prolonged in end-stage renal disease.11 Consequently, some researchers12 use INH in half doses (5 mg/kg) per day. However, others prefer to use the full dose. In our study, we prescribe a full dose with good tolerance even in slow acetylates. We recommend giving the dose of INH on dialysis days after the dialysis session. The neurological side effects of INH are preventable by adding pyridoxine in doses of 50 mg per day (half of the recommended adult dose). The usual dose of RIF is recommended because its metabolism does not depend on renal function.13 EMB is usually given in a dose of 20 mg/kg three times a week after each hemodialysis session. In the same way, we can prescribe the PZA at a dose of 20 to 25 mg/kg.13 In children on dialysis, the duration of treatment in accordance with new recommendations is 12 months (with INH and RIF and with EMB and PZA added for the first two months).5 We strongly recommend this protocol to avoid the resistance and resurgence of TB after kidney transplantation. The efficiency of this protocol is only possible if the treatment is well monitored and tolerated.14 In our study, the outcome was fatal for a patient with miliary TB despite intravenous INH and RIF.

Conclusion

Dialysis patients and especially children are at high risk of TB. Physicians caring for dialysis children must remain vigilant for signs of TB in this vulnerable population. Two basic points emerge throughout our study and literature review: Diagnostic difficulties of the disease are due to the insidious and nonspecific clinical presentation and difficulties in identifying the mycobacterium TB by conventional methods. The outcome is often favorable when treatment starts at an early stage and the duration is long enough.
  13 in total

1.  Tuberculosis in patients undergoing maintenance dialysis.

Authors:  M M Hussein; N Bakir; H Roujouleh
Journal:  Nephrol Dial Transplant       Date:  1990       Impact factor: 5.992

Review 2.  Therapeutic drug monitoring in the treatment of tuberculosis.

Authors:  Charles A Peloquin
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Extrapulmonary tuberculosis in patients with end stage renal disease--two case reports and a brief review.

Authors:  R J Lund; M J Koch; J B Oldemeyer; A J Meares; R W Dunlay
Journal:  Int Urol Nephrol       Date:  2000       Impact factor: 2.370

4.  Tuberculosis in children undergoing continuous ambulatory peritoneal dialysis.

Authors:  M Ekim; N Tümer; S Bakkaloğlu
Journal:  Pediatr Nephrol       Date:  1999-09       Impact factor: 3.714

Review 5.  Isoniazid-induced neurotoxicity in chronic dialysis patients: report of three cases and a review of the literature.

Authors:  M S Siskind; D Thienemann; L Kirlin
Journal:  Nephron       Date:  1993       Impact factor: 2.847

6.  Increased incidence of tuberculosis in patients undergoing hemodialysis.

Authors:  K Cengiz
Journal:  Nephron       Date:  1996       Impact factor: 2.847

Review 7.  Aspects of immune dysfunction in end-stage renal disease.

Authors:  Sawako Kato; Michal Chmielewski; Hirokazu Honda; Roberto Pecoits-Filho; Seiichi Matsuo; Yukio Yuzawa; Anders Tranaeus; Peter Stenvinkel; Bengt Lindholm
Journal:  Clin J Am Soc Nephrol       Date:  2008-08-13       Impact factor: 8.237

8.  High prevalence of latent tuberculosis infection in patients in end-stage renal disease on hemodialysis: Comparison of QuantiFERON-TB GOLD, ELISPOT, and tuberculin skin test.

Authors:  S S J Lee; K J Chou; I J Su; Y S Chen; H C Fang; T S Huang; H C Tsai; S R Wann; H H Lin; Y C Liu
Journal:  Infection       Date:  2008-12-10       Impact factor: 3.553

9.  Detecting latent tuberculosis infection in hemodialysis patients: a head-to-head comparison of the T-SPOT.TB test, tuberculin skin test, and an expert physician panel.

Authors:  Laura Passalent; Kamran Khan; Robert Richardson; Jun Wang; Helen Dedier; Michael Gardam
Journal:  Clin J Am Soc Nephrol       Date:  2006-10-18       Impact factor: 8.237

Review 10.  Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure.

Authors:  Vincent Launay-Vacher; Hassane Izzedine; Gilbert Deray
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.